logo/base Created with Sketch.
See product brochures

Agile 3+

Identification of advanced fibrosis in MASLD patients

Agile 3+ is a FibroScan®-based Score 

chevron chevron

Agile 3+ Target

Although MASLD is the most common chronic liver disease worldwide, early intervention can reverse liver damage and improve patient outcomes. Identifying patients with advanced fibrosis (F≥3 according to MASH CRN scoring system) is key for the management of patients with MASFD since they are at increased risk of developing liver-related complications.

Discover Scores

Agile 3+ Construction

Agile 3+ combines LSM by VCTE® with readily available blood biomarkers (AST, ALT, platelets) to aid in the identification of advanced fibrosis in patients with MASLD, offering optimised positive predictive values compared to LSM alone, and to assist in the prediction of liver complications.

Agile 3+ Performance

High clinical performances demonstrated in large external validation cohorts from different geographical origins.

Clinical validation: Sanyal et al., Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with MASLD using FibroScanbased Agile scores, Journal of Hepatology, 2022.

Our liver health solutions

  • Liver Health Management

    Liver Health Management

    Cloud-based solution to assist clinicians in providing comprehensive liver care.

    chevron

  • Agile 4

    Identification of cirrhosis in patients with MASLD

    chevron

  • Fast

    Identification of at-risk MASH patients

    chevron
  • FibroScan® Mini+ 430

    FibroScan® by echosens

    The non-invasive solution for comprehensive management of liver health

    chevron

Agile 3+: tried and trusted

Agile 3+ and Agile 4 well predict the occurrence of liverrelated events in patients with MASLD. Particularly, rule-in cut-offs of both scores better identify at-risk patients than LSM alone. These results demonstrate the interest of those scores in the identification of patients requiring hepatocellular carcinoma and esophageal varices screening.

J. Boursier et all.

ILC 2021

A novel noninvasive score including LSM by VCTE and routine clinical parameters improves the identification of advanced fibrosis among patients with MASLD and may reduce the necessity of liver biopsy in this patient population. In addition, external validation on primary and secondary care centers could assess its potential as a new tool to refer patients to liver specialists.

A.J. Sanyal et all.

ILC 2021

Discover the clinical evidence chevron

Request a demo!

Interested in FibroScan®?

Contact us

Agile 3+ is a class I medical device according to Directive 93/42/EEC.Agile 3+ calculator is a tool for clinicians, computed from LSM (obtained from FibroScan® device), AST, ALT, platelets, diabetes status, age and gender, to aid in the identification of patients with suspicion of MASLD as having advanced fibrosis. It was developed based on a pool of retrospective cohorts and published in peer-reviewed literature. Agile 3+ is presented as an educational service intended for licensed healthcare professionals. While this score is about specific medical and health issues, it is not a substitute for or a replacement of personalized medical advice and is not intended to be used as the sole basis for making individualized medical or health-related decisions.

*MASLD/MASH is formerly knowed as NAFLD/NASH

To access the Agile 3+ User Guides, connect to myfibroscan.com:
Scores > Agile 3+ > Learn more